Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis

Executive Kyung-Ah Kim Sees Opportunity To Lead On Ophthalmic Biosimilars

 
• By David Wallace
  
Eye USA Flag Face
Samsung Bioepis recently gained the first US ophthalmic biosimilar approval • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products